PMID: 
Reviews - 2jdr mentioned but not cited (2)
- Chiral kinase inhibitors. Jiang JK, Shen M, Thomas CJ, Boxer MB. Curr Top Med Chem 11 800-809 (2011)
- Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein. Primavera E, Palazzotti D, Barreca ML, Astolfi A. Pharmaceuticals (Basel) 16 993 (2023)
Articles - 2jdr mentioned but not cited (13)
- Inhibitor hijacking of Akt activation. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. Nat Chem Biol 5 484-493 (2009)
- Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway. Mohan CD, Srinivasa V, Rangappa S, Mervin L, Mohan S, Paricharak S, Baday S, Li F, Shanmugam MK, Chinnathambi A, Zayed ME, Alharbi SA, Bender A, Sethi G, Basappa, Rangappa KS. PLoS One 11 e0153155 (2016)
- Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway. Liao XZ, Tao LT, Liu JH, Gu YY, Xie J, Chen Y, Lin MG, Liu TL, Wang DM, Guo HY, Mo SL. Cancer Cell Int 17 124 (2017)
- Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way. Xie J, Liu JH, Liu H, Liao XZ, Chen Y, Lin MG, Gu YY, Liu TL, Wang DM, Ge H, Mo SL. BMC Cancer 16 899 (2016)
- Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Akt2 inhibitors. Fei J, Zhou L, Liu T, Tang XY. Int J Med Sci 10 265-275 (2013)
- Retinal Protection and Distribution of Curcumin in Vitro and in Vivo. Platania CBM, Fidilio A, Lazzara F, Piazza C, Geraci F, Giurdanella G, Leggio GM, Salomone S, Drago F, Bucolo C. Front Pharmacol 9 670 (2018)
- Synthesis and evaluation of indazole based analog sensitive Akt inhibitors. Okuzumi T, Ducker GS, Zhang C, Aizenstein B, Hoffman R, Shokat KM. Mol Biosyst 6 1389-1402 (2010)
- Kinase Inhibitory Activities and Molecular Docking of a Novel Series of Anticancer Pyrazole Derivatives. Nossier ES, Abd El-Karim SS, Khalifa NM, El-Sayed AS, Hassan ESI, El-Hallouty SM. Molecules 23 E3074 (2018)
- In Silico Investigation of the Anti-Tumor Mechanisms of Epigallocatechin-3-Gallate. Wang W, Xiong X, Li X, Zhang Q, Yang W, Du L. Molecules 24 E1445 (2019)
- Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation. Trafalis DT, Sagredou S, Dalezis P, Voura M, Fountoulaki S, Nikoleousakos N, Almpanakis K, Deligiorgi MV, Sarli V. Pharmaceutics 13 493 (2021)
- Globospiramine from Voacanga globosa Exerts Robust Cytotoxic and Antiproliferative Activities on Cancer Cells by Inducing Caspase-Dependent Apoptosis in A549 Cells and Inhibiting MAPK14 (p38α): In Vitro and Computational Investigations. Manzano JAH, Abellanosa EA, Aguilar JP, Brogi S, Yen CH, Macabeo APG, Austriaco N. Cells 13 772 (2024)
- Identification of Dual-Target Inhibitors for Epidermal Growth Factor Receptor and AKT: Virtual Screening Based on Structure and Molecular Dynamics Study. Yang H, Zhang Z, Liu Q, Yu J, Liu C, Lu W. Molecules 28 7607 (2023)
- Network Analyses Based on Machine Learning Methods to Quantify Effects of Peptide-Protein Complexes as Drug Targets Using Cinnamon in Cardiovascular Diseases and Metabolic Syndrome as a Case Study. Wang Y, Wang L, Liu Y, Li K, Zhao H. Front Genet 12 816131 (2021)
Reviews citing this publication (5)
- Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Garcia-Echeverria C, Sellers WR. Oncogene 27 5511-5526 (2008)
- Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Miller TW, Balko JM, Arteaga CL. J Clin Oncol 29 4452-4461 (2011)
- Structure-based design of molecular cancer therapeutics. van Montfort RL, Workman P. Trends Biotechnol 27 315-328 (2009)
- Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Arteaga CL. Curr Top Microbiol Immunol 347 189-208 (2010)
- Autoregulation of kinase dephosphorylation by ATP binding in AGC protein kinases. Chan TO, Pascal JM, Armen RS, Rodeck U. Cell Cycle 11 475-478 (2012)
Articles citing this publication (36)
- Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Kuijl C, Savage ND, Marsman M, Tuin AW, Janssen L, Egan DA, Ketema M, van den Nieuwendijk R, van den Eeden SJ, Geluk A, Poot A, van der Marel G, Beijersbergen RL, Overkleeft H, Ottenhoff TH, Neefjes J. Nature 450 725-730 (2007)
- Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. Mol Pharmacol 80 565-572 (2011)
- Measuring and interpreting the selectivity of protein kinase inhibitors. Smyth LA, Collins I. J Chem Biol 2 131-151 (2009)
- Crystal structure of a human IκB kinase β asymmetric dimer. Liu S, Misquitta YR, Olland A, Johnson MA, Kelleher KS, Kriz R, Lin LL, Stahl M, Mosyak L. J Biol Chem 288 22758-22767 (2013)
- Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Chan TO, Zhang J, Rodeck U, Pascal JM, Armen RS, Spring M, Dumitru CD, Myers V, Li X, Cheung JY, Feldman AM. Proc Natl Acad Sci U S A 108 E1120-7 (2011)
- Crystal structure of human CDC7 kinase in complex with its activator DBF4. Hughes S, Elustondo F, Di Fonzo A, Leroux FG, Wong AC, Snijders AP, Matthews SJ, Cherepanov P. Nat Struct Mol Biol 19 1101-1107 (2012)
- Insights into the conformational variability and regulation of human Nek2 kinase. Westwood I, Cheary DM, Baxter JE, Richards MW, van Montfort RL, Fry AM, Bayliss R. J Mol Biol 386 476-485 (2009)
- Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Mol Cancer Ther 10 360-371 (2011)
- AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD. Mol Cancer Ther 9 1100-1110 (2010)
- Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M, Davies TG, Fazal L, Seavers L, Raynaud FI, Eccles SA, Aherne GW, Garrett MD, Collins I. J Med Chem 53 2239-2249 (2010)
- Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. Vyas VK, Ghate M, Goel A. J Mol Graph Model 42 17-25 (2013)
- Protein kinase-inhibitor database: structural variability of and inhibitor interactions with the protein kinase P-loop. Patel RY, Doerksen RJ. J Proteome Res 9 4433-4442 (2010)
- Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations. Mahalapbutr P, Wonganan P, Chavasiri W, Rungrotmongkol T. Cancers (Basel) 11 E437 (2019)
- The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Couty S, Westwood IM, Kalusa A, Cano C, Travers J, Boxall K, Chow CL, Burns S, Schmitt J, Pickard L, Barillari C, McAndrew PC, Clarke PA, Linardopoulos S, Griffin RJ, Aherne GW, Raynaud FI, Workman P, Jones K, van Montfort RL. Oncotarget 4 1647-1661 (2013)
- In search of AKT kinase inhibitors as anticancer agents: structure-based design, docking, and molecular dynamics studies of 2,4,6-trisubstituted pyridines. Trejo-Soto PJ, Hernández-Campos A, Romo-Mancillas A, Medina-Franco JL, Castillo R. J Biomol Struct Dyn 36 423-442 (2018)
- Discovery of a novel protein kinase B inhibitor by structure-based virtual screening. Medina-Franco JL, Giulianotti MA, Yu Y, Shen L, Yao L, Singh N. Bioorg Med Chem Lett 19 4634-4638 (2009)
- 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics. Zeng Q, Bourbeau MP, Wohlhieter GE, Yao G, Monenschein H, Rider JT, Lee MR, Zhang S, Lofgren J, Freeman D, Li C, Tominey E, Huang X, Hoffman D, Yamane H, Tasker AS, Dominguez C, Viswanadhan VN, Hungate R, Zhang X. Bioorg Med Chem Lett 20 1652-1656 (2010)
- Advances in fragment-based drug discovery platforms. Orita M, Warizaya M, Amano Y, Ohno K, Niimi T. Expert Opin Drug Discov 4 1125-1144 (2009)
- Addressing the Glycine-Rich Loop of Protein Kinases by a Multi-Facetted Interaction Network: Inhibition of PKA and a PKB Mimic. Lauber BS, Hardegger LA, Alam KA, Lund BA, Dumele O, Harder M, Kuhn B, Engh RA, Diederich F. Chemistry 22 211-221 (2016)
- Elucidation of binding mode and three dimensional quantitative structure-activity relationship studies of a novel series of protein kinase B/Akt inhibitors. Muddassar M, Pasha FA, Neaz MM, Saleem Y, Cho SJ. J Mol Model 15 183-192 (2009)
- Quantum mechanical pairwise decomposition analysis of protein kinase B inhibitors: validating a new tool for guiding drug design. Zhang X, Gibbs AC, Reynolds CH, Peters MB, Westerhoff LM. J Chem Inf Model 50 651-661 (2010)
- 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity. Lin H, Yamashita DS, Zeng J, Xie R, Wang W, Nidarmarthy S, Luengo JI, Rhodes N, Knick VB, Choudhry AE, Lai Z, Minthorn EA, Strum SL, Wood ER, Elkins PA, Concha NO, Heerding DA. Bioorg Med Chem Lett 20 673-678 (2010)
- Akt kinase C-terminal modifications control activation loop dephosphorylation and enhance insulin response. Chan TO, Zhang J, Tiegs BC, Blumhof B, Yan L, Keny N, Penny M, Li X, Pascal JM, Armen RS, Rodeck U, Penn RB. Biochem J 471 37-51 (2015)
- Engineering Archeal Surrogate Systems for the Development of Protein-Protein Interaction Inhibitors against Human RAD51. Moschetti T, Sharpe T, Fischer G, Marsh ME, Ng HK, Morgan M, Scott DE, Blundell TL, R Venkitaraman A, Skidmore J, Abell C, Hyvönen M. J Mol Biol 428 4589-4607 (2016)
- Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase. Pflug A, de Oliveira TM, Bossemeyer D, Engh RA. Biochem J 440 85-93 (2011)
- Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors. Lu Y, Knapp M, Crawford K, Warne R, Elling R, Yan K, Doyle M, Pardee G, Zhang L, Ma S, Mamo M, Ornelas E, Pan Y, Bussiere D, Jansen J, Zaror I, Lai A, Barsanti P, Sim J. J Mol Biol 429 1684-1704 (2017)
- Rationally designed PKA inhibitors for positron emission tomography: Synthesis and cerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide. Vasdev N, LaRonde FJ, Woodgett JR, Garcia A, Rubie EA, Meyer JH, Houle S, Wilson AA. Bioorg Med Chem 16 5277-5284 (2008)
- AKT capture by feline leukemia virus. Kawamura M, Umehara D, Odahara Y, Miyake A, Ngo MH, Ohsato Y, Hisasue M, Nakaya MA, Watanabe S, Nishigaki K. Arch Virol 162 1031-1036 (2017)
- Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. Chen SF, Cao Y, Chen JJ, Chen JZ. J Mol Model 19 5097-5112 (2013)
- Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2. Ashton KS, St Jean DJ, Poon SF, Lee MR, Allen JG, Zhang S, Lofgren JA, Zhang X, Fotsch C, Hungate R. Bioorg Med Chem Lett 21 5191-5196 (2011)
- Theory of docking scores and its application to a customizable scoring function. Takahashi O, Masuda Y, Muroya A, Furuya T. SAR QSAR Environ Res 21 547-558 (2010)
- Molecular docking appraisal of Dysphania ambrosioides phytochemicals as potential inhibitor of a key triple-negative breast cancer driver gene. Anifowose LO, Paimo OK, Adegboyega FN, Ogunyemi OM, Akano RO, Hammad SF, Ghazy MA. In Silico Pharmacol 11 15 (2023)
- Molecular dynamics simulation on the allosteric analysis of the c-di-GMP class I riboswitch induced by ligand binding. Li C, Zhao X, Xie P, Hu J, Bi H. J Mol Recognit 32 e2756 (2019)
- Synthesis and evaluation of heteroaryl substituted diazaspirocycles as scaffolds to probe the ATP-binding site of protein kinases. Allen CE, Chow CL, Caldwell JJ, Westwood IM, van Montfort RL, Collins I. Bioorg Med Chem 21 5707-5724 (2013)
- Allyl ether of mansonone G as a potential anticancer agent for colorectal cancer. Chanvijit S, Phuagkhaopong S, Mahalapbutr P, Klaewkla M, Chavasiri W, Wonganan P. Sci Rep 12 19668 (2022)
- Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy. Erdönmez B, Altıntop MD, Akalın Çiftçi G, Özdemir A, Ece A. ACS Omega 8 20056-20065 (2023)